Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00080262 · ClinicalTrials.gov registry record · Phase 2

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

A Phase 2 study of Breast Cancer and Metastases, sponsored by R-Pharm.

Completed
Registry status
Phase 2
Development phase
125
Enrollment target
20
Study locations

NCT00080262 is a Phase 2 study of Breast Cancer and Metastases that has completed, run by R-Pharm. The registered enrollment target is 125 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00080262, a Phase 2 study of Breast Cancer and Metastases, has completed, sponsored by R-Pharm.

COMPLETED
Registry status
Phase 2
Development phase
125 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.

Conditions Studied

Breast Cancer Metastases

Interventions

  • DRUG Ixabepilone

Study Locations (20)

Tennessee

  • Local Institution - Chattanooga
  • Local Institution - Jackson
  • Local Institution - Knoxville
  • Local Institution - Nashville

North Carolina

  • Local Institution - Asheville
  • Local Institution - Charlotte

Texas

  • Local Institution - Houston
  • Local Institution - San Antonio

Other

  • Local Institution - Buenos Aires
  • Local Institution - Santa Fe

California

  • Local Institution - La Verne

Connecticut

  • Local Institution - Meriden

Florida

  • Local Institution - Jacksonville

Maryland

  • Local Institution - Baltimore

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2004-02
Est. Completion 2006-12
Phase Phase 2

Sponsor

R-Pharm

19 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00080262

The ClinicalTrials.gov registry entry for NCT00080262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ixabepilone is the first listed.

NCT00080262 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Tennessee, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT00080262 about?

NCT00080262 is a clinical study titled "Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)". The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.

What is the current status of trial NCT00080262?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2004-02. Estimated completion is 2006-12.

What conditions does trial NCT00080262 study?

This clinical trial studies the following conditions: Breast Cancer, Metastases.

What interventions are being tested in trial NCT00080262?

The interventions under investigation include: Ixabepilone (DRUG).

Who is sponsoring clinical trial NCT00080262?

This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00080262 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Metastases

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.